The most common question women bring to their doctors during perimenopause is not, in fact, about hot flashes. It is a quieter, more unsettling question, usually delivered with a slightly embarrassed laugh: 'Is something wrong with me?' The sleeplessness that arrives without warning. The anxiety that appears in women who have never been anxious. The rage that surfaces in women who have always been calm. The forgetting — of words, of names, of the reason they walked into a room.
Something is happening. But nothing is wrong.
Perimenopause — the hormonal transition that precedes menopause, typically beginning anywhere from two to twelve years before the final menstrual period — is one of the most profoundly underresearched and underacknowledged experiences in women's medicine. The average woman enters it somewhere in her mid-to-late forties with essentially no preparation, no framework for understanding what is occurring, and very little support from a medical system that has historically been better at diagnosing conditions than navigating transitions.
What is actually happening is this: estrogen and progesterone, which have regulated not only the reproductive cycle but also sleep architecture, mood, cognition, cardiovascular health, bone density, and skin integrity, begin to fluctuate in patterns that are neither linear nor predictable. It is not a steady decline — it is a turbulence.
The brain, it is worth noting, is exquisitely sensitive to estrogen. There are estrogen receptors throughout the cerebral cortex, in the hippocampus, in the regions responsible for verbal memory and executive function. When estrogen fluctuates, cognitive function fluctuates with it. The 'brain fog' that women describe is not imagined and is not permanent. It is neurological. And it is, in many women, reversible.
The question is not whether to address perimenopause. The question is how honestly and how early you are willing to have the conversation about what is actually happening in your body.
The decision about whether to use hormone therapy is deeply personal and depends on individual health history, risk factors, and symptom burden. What is no longer medically defensible is the idea that hormone therapy is categorically dangerous for all women. The scientific consensus has moved significantly. For women who begin hormone therapy within ten years of menopause or before the age of sixty, the risk profile is, for most women, not only acceptable but favorable.
This is not medical advice. It is an invitation to take your own biology seriously, to find a provider who will do the same, and to approach this decade not as a surrender to decline but as an opportunity to understand your body at a level of nuance you have perhaps never been offered before.
Questions Women Ask
What are the first signs of perimenopause?
Rarely the hot flash — that comes later, if at all. The early signs are quieter: sleep that breaks at three in the morning for no reason, anxiety in women who have never been anxious, a shorter fuse, words that slip away mid-sentence, periods that begin arriving on their own schedule. If several of these feel familiar and you are in your forties, you are not imagining a pattern. You are in one.
How long does perimenopause last?
Anywhere from two to twelve years, with four being about average. It ends twelve months after the final menstrual period — the formal definition of menopause. The wide range is one reason so many women feel unmoored: there is no map handed to you, only the gradual recognition that the terrain has changed.
Is hormone therapy safe?
For most women who begin it within ten years of menopause or before age sixty, the current scientific consensus is that the benefits outweigh the risks — a significant reversal from the fear that followed the 2002 Women's Health Initiative headlines. The decision is individual and belongs in a real conversation with a provider who knows this literature. What is no longer defensible is refusing the conversation altogether.
This article is written for educational purposes and does not constitute medical advice. Consult a licensed healthcare provider for diagnosis and treatment. Sources available below.
References
On Perimenopause — Definition, Duration & Symptoms
- "Perimenopause." Mayo Clinic. mayoclinic.org
- Santoro N. "Perimenopause: From Research to Practice." Journal of Women's Health. 2016;25(4):332–339. pmc.ncbi.nlm.nih.gov
- Delamater L, Santoro N. "Management of the Perimenopause." Clinical Obstetrics and Gynecology. 2018;61(3):419–432. pmc.ncbi.nlm.nih.gov
On Estrogen, Brain Function & "Brain Fog"
- Brinton RD, et al. "Perimenopause as a Neurological Transition State." Nature Reviews Endocrinology. 2015;11(7):393–405. pmc.ncbi.nlm.nih.gov
- Maki PM, Henderson VW. "Cognition and the Menopause Transition." Menopause. 2016;23(7):803–805. pubmed.ncbi.nlm.nih.gov
- Greendale GA, et al. "Effects of the Menopause Transition and Hormone Use on Cognitive Performance in Midlife Women." Neurology. 2009;72(21):1850–1857. pmc.ncbi.nlm.nih.gov
On Mood, Anxiety & Sleep in Perimenopause
- Bromberger JT, Kravitz HM. "Mood and Menopause: Findings from the Study of Women's Health Across the Nation (SWAN)." Obstetrics and Gynecology Clinics of North America. 2011;38(3):609–625. pmc.ncbi.nlm.nih.gov
- Baker FC, et al. "Sleep and Sleep Disorders in the Menopausal Transition." Sleep Medicine Clinics. 2018;13(3):443–456. pmc.ncbi.nlm.nih.gov
On Hormone Therapy — The "Timing Hypothesis"
- "The 2022 Hormone Therapy Position Statement of The North American Menopause Society." Menopause. 2022;29(7):767–794. menopause.org
- Manson JE, et al. "Menopausal Hormone Therapy and Long-Term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials." JAMA. 2017;318(10):927–938. pubmed.ncbi.nlm.nih.gov
- Hodis HN, Mack WJ. "Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing." The Cancer Journal. 2022;28(3):208–223. pubmed.ncbi.nlm.nih.gov